IN THE CLAIMS

Claims 1-27 have been cancelled. Claims 33-35 have been added. Please amend claims 28-32 as follows:

1- 27 (Cancelled)

28. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of S-tofisopam, a prodrug or pharmaceutically acceptable salt thereof, substantially free of its R-enantiomer, with a pharmaceutically acceptable carrier, wherein the composition is for intraperitoneal, subcutaneous, intranasal, intramuscular, intrathecal, sublingual, rectal, intravenous infusion, or transdermal delivery.

29. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of S-tofisopam, a prodrug or pharmaceutically acceptable salt thereof, substantially free of its R-enantiomer, with a pharmaceutically acceptable carrier, wherein the amount

of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 10 mg to 1200 mg.

30. (Currently amended) The pharmaceutical composition according to claim 29, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 50 mg to 600 mg.

31. (Currently amended) The pharmaceutical composition according to claim 29, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 100 mg to 400 mg.

32. (Currently amended) A method of administering a pharmaceutical composition comprising a therapeutically effective amount of S-tofisopam, a prodrug or pharmaceutically acceptable salt thereof, substantially free of its R-enantiomer, with a pharmaceutically acceptable carrier, comprising preparing the pharmaceutical composition comprising of S-tofisopam, pro-drug or pharmaceutically acceptable salt thereof and administering the pharmaceutical composition at a dose of less than 30 mg/kg.

33. (New) A pharmaceutical composition according to claim 28, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 10 mg to 1200 mg.

34. (New) The pharmaceutical composition according to claim 28, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 50 mg to 600 mg.

35. (New) The pharmaceutical composition according to claim 29, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 100 mg to 400 mg.